Efficacy and Safety of a Intra-articular Injection, ENKO1, in Patients With Symptomatic Knee Osteoarthritis.

Osteoarthritis, Knee Clinical Trial

— ENKORE  

Official title:

Comparative Study of the Efficacy and Safety of an Intra-articular Injection of ENKO 1 vs Durolane in Patients With Symptomatic Osteoarthritis of the Knee.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03762408
• Other study ID #: OPK-ENK-2017-01
• Status: Completed
• Phase: N/A
• Start date: December 15, 2017
• Est. completion date: May 29, 2020

Study information

• Verified date: March 2021
• Source: OPKO Health, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Clinical trial with medical device, multicenter, single-blind (blind third party evaluation), randomized, comparative and in two paralell groups, to demonstrate the treatment according to usual clinical practice, of the combination of 50 mg Sodium Hyaluronate and 50 mg Chondroitin Sulfate (ENKO 1) in a single administration, has non-inferiority efficacy vs the comparator (Durolane; 60 mg HA crosslinked) in patients with symptomatic knee osteoarthritis after three months of follow-up.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 175
• Est. completion date: May 29, 2020
• Est. primary completion date: May 29, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Medial femorotibial compartment knee OA.

• Fulfilment of ACR criteria for knee OA (knee pain + grinding + stiffness in the morning < 30 minutes).

• Patients with a clinical course of disease longer than 6 months.

• Global pain score greater than 60 mm on a 0-100 mm VAS on the knee under study.

• Grade II or III according to the Kellgren and Lawrence classification system for the knee under study (on a posteroanterior X-ray performed under weight-bearing and for 6 months before randomisation).

• Patients taking analgesics for at least 3 months before randomisation and whom are dissatisfied with their current therapy.

• Patients who have given their consent in writing to take part in the study.

• Woman of childbearing age must take a urine pregnancy test which must be negative at the randomisation visit and be currently using an effective contraceptive method for at least 2 menstrual cycles (oral contraceptives, intrauterine device, tubal ligation or other effective procedures).

Exclusion Criteria:

• Isolated symptomatic patellofemoral osteoarthritis.

• Microcrystalline osteoarthritis.

• Prosthesis in knee under study.

• Joint lavage or arthroscopy or any surgery on the knee under study in the 6 months before randomisation.

• Paget's disease of bone, chondromatosis or villonodular sinovitis.

• Inflammatory, infectious or metabolic arthritis (rheumatoid arthritis, spondyloarthropathy or connective tissue diseases).

• Haemochromatosis, ochronosis or haemophilia.

• History of diseases that the investigator considers likely to interfere with the functional disability assessment.

• Knee surgery planned during the study period.

Other disease-related criteria:

• BMI greater than or equal to 30.

• Immunodeficiency or a serious or progressive disease (heart, lung, liver, kidney, haematological, neoplastic or infectious disease).

• Skin diseases or infections in the area of the injection site.

• Previous history of venous thromboembolism (including pulmonary embolism) or high risk of venous thromboembolism.

• Venous or lymphatic stasis of the leg under study.

• Severe acute or chronic disease that the investigator considers incompatible with the conduct of the study.

• Disease that the investigator considers likely to interfere with the study results or to expose the patient to an additional risk.

• Alcohol or drug abuse or dependence.

Previous or concomitant treatment-related criteria:

• Patients who have taken a SYSADOA, SERM or a drug/dietary supplement containing glucosamine, chondroitin sulfate, diacerein or avocado-soybean extracts in the 3 months before randomisation

• Patients who have taken paracetamol in the 24 hours before randomisation or any other symptomatic analgesic drug, including NSAIDs (except aspirin up to 325 mg/day for cardiovascular prophylaxis), in the 48 hours before randomisation

• Patients who have received any corticosteroid treatment by any route of administration (other than inhalers or the ocular or auricular routes) in the month before randomisation

• Patients who have received an intra-articular steroid injection in the knee under study in the month before randomisation or patients who have received intra-articular hyaluronic acid in the target knee in the 6 months before randomisation

• Patients who have received any local or topical treatment on the target knee in the 2 weeks before randomisation

Criteria related to concomitant medication:

• Hypersensitivity to paracetamol or NSAIDs

Study product-related criteria:

• Known allergy to the study treatments or to any of its ingredients.

Other criteria:

• Patients likely to be unable to comply with the protocol instructions and/or treatment, in the investigator's opinion

• Patients who have taken part in a clinical trial in the preceding 2 months or taking part in a trial at the time of randomisation

• Patients linguistically or mentally incapable of understanding the nature, objectives and possible consequences of the study; or who refuse to be subject to its limitations

• Patients who are family or colleagues (secretary, nurse, technician, etc.) of the investigator.

• Women: pregnant or breastfeeding

Related Conditions & MeSH terms

• Osteoarthritis
• Osteoarthritis, Knee

Intervention

Device:
• ENKO 1
50 mg of HA/ 50 mg of CS in 5 ml
• Durolane
60 mg HA crosslinked in 3 ml

Locations

Country	Name	City	State
Spain	Instituto Médico Arriaza	A Coruña
Spain	Hospital Clínic de Barcelona	Barcelona
Spain	Hospital del Mar	Barcelona
Spain	Hospital Sant Rafael	Barcelona
Spain	Instituto POAL del Reumatología	Barcelona
Spain	Clínica Novo Sancti Petri	Chiclana de la Frontera	Cádiz
Spain	Clínica Diagonal	Esplugues De Llobregat	Barceloma
Spain	Consell calatà de l'Esport	Esplugues De Llobregat	Barcelona
Spain	BiClinic	Madrid
Spain	AMS Centro Médico del Ejercicio	Málaga
Spain	Clínica Dr. Casermeiro	Mijas Costa	Málaga
Spain	Clínica ISMEC	Sevilla
Spain	Consorci Sanitari de Terrassa	Terrassa	Barcelona
Spain	Clínica IQTRA	Torrejón De Ardoz	Madrid
Spain	Hospital de Torrelodones	Torrelodones	Madrid
Spain	Clínica Gastaldi	Valencia
Spain	Clínica Traumatológica Dr. Baró	Valladolid
Spain	Hospital Vithas San José	Vitoria Gasteiz

Sponsors (2)

Lead Sponsor	Collaborator
OPKO Health, Inc.	Osteoarthritis Foundation International (OAFI)

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pain Relief	Assessed using VAS (Visual Analogue Scale) Huskisson 0-100mm; Pain relief scored on a scale of 0 to 10.; 0 means No pain and 10 means worst possible pain.	Change from baseline pain relief at 6 months.
Secondary	Pain Relief	Assessed using VAS (Visual Analogue Scale) Huskisson 0-100mm; Pain relief scored on a scale of 0 to 10.; 0 means No pain and 10 means Worst possible pain.	0, 1, 6 and 12 weeks.
Secondary	Evaluation of functional WESTERN ONTARIO AND MCMASTER OSTEOARTHRITIS INDEX (WOMAC) index score (Pain subscale)	Validated questionnaire for patients with osteoarthritis of the knee. 5 items: during walking, using stairs, in bed, sitting or lying, and standing upright.; The test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4).; The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. Usually a sum of the scores for all three subscales gives a total WOMAC score.; Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.	-7, 0, 1, 6, 12 and 24 weeks.
Secondary	Evaluation of functional WESTERN ONTARIO AND MCMASTER OSTEOARTHRITIS INDEX (WOMAC) index score (Stiffness subscale)	Validated questionnaire for patients with osteoarthritis of the knee. 2 items: after first waking and later in the day. The test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4).; The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. Usually a sum of the scores for all three subscales gives a total WOMAC score.; Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.	-7, 0, 1, 6, 12 and 24 weeks.
Secondary	Evaluation of functional WESTERN ONTARIO AND MCMASTER OSTEOARTHRITIS INDEX (WOMAC) index score (Functional capacity subscale)	Validated questionnaire for patients with osteoarthritis of the knee. 17 items): using stairs, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on / taking off socks, rising from bed, lying in bed, getting in / out of bath, sitting, getting on / off toilet, heavy domestic duties, light domestic duties.; The test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4).; The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. Usually a sum of the scores for all three subscales gives a total WOMAC score.; Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.	-7, 0, 1, 6, 12 and 24 weeks.
Secondary	Evaluation of percentage of patients who respond to treatment	Evaluation of percentage of patients who respond to treatment according to the OMERACT-OARSI criteria.	0, 1, 6, 12 and 24 weeks.
Secondary	Global evaluation of the activity of the disease and of the respond to treatment by patient.	Global evaluation of the activity of disease by the patient (VAS (Visual Analogue Scale) from 0-100mm).; Scale from 0 to 10, which correspond to: Mild (0-2), Moderate (3-7) and Intense (8-10).; where 0 is better outcome and 10 is the worst outcome.	0, 1, 6, 12 and 24 weeks.
Secondary	Evaluation of Health status of patients	Evaluation of Health status by quality of life questionnaire 12-Item Short Form Survey (SF-12).; It consists of 12 items from the 8 dimensions of the SF-36 Physical Function, Social Function, Physical Role, Emotional Role, Mental Health, Vitality, Body Pain, General Health and evaluate intensity and frequency of each item.; Scale ranges: Minimum 12 and maximum 60 scores. When 12 means better and 60 is the worse outcome.	0, 1, 6, 12 and 24 weeks.
Secondary	Evaluation of concomitant medication intake	Daily intake of Paracetamol (maximum 3g/day)	-7, 0, 1, 6, 12 and 24 weeks.
Secondary	Evaluation of synovitis	Clinical valoration of synovial joint swelling.	-7, 0, 1, 6, 12 and 24 weeks.
Secondary	Biomarkers	Blood sample analysis of serum soluble biomarkers according to current validation by THE BIOMARKERS CONSORTIUM.; Pre-selected biomarkers: Concentration of Serum CTXI, Serum NTXI, Serum-HA, Serum-PIIANP and Serum CTXII.	-7 and 12 weeks
Secondary	Adverse events	Number of Participants with any Adverse event.	0, 1, 6, 12 and 24 weeks.